Next Article in Journal
Why do We Find It so Hard to Discuss Spirituality? A Qualitative Exploration of Attitudinal Barriers
Next Article in Special Issue
TGF-β Signaling in Bone Remodeling and Osteosarcoma Progression
Previous Article in Journal
Pulmonary Hypertension Due to Common Respiratory Conditions: Classification, Evaluation and Management Strategies
Previous Article in Special Issue
Mechanisms of TGFβ-Induced Epithelial–Mesenchymal Transition
Open AccessFeature PaperReview

Dysregulation of TGFβ1 Activity in Cancer and Its Influence on the Quality of Anti-Tumor Immunity

Department of Biology, Hampden-Sydney College, Hampden-Sydney, VA 23943, USA
Academic Editor: Andrei Turtoi
J. Clin. Med. 2016, 5(9), 76; https://doi.org/10.3390/jcm5090076
Received: 20 July 2016 / Revised: 26 August 2016 / Accepted: 29 August 2016 / Published: 31 August 2016
(This article belongs to the Special Issue Biological and Clinical Aspects of TGF-beta in Carcinogenesis)
TGFβ1 is a pleiotropic cytokine that exhibits a variety of physiologic and immune regulatory functions. Although its influence on multiple cell types is critical for the regulation of numerous biologic processes in the host, dysregulation of both TGFβ1 expression and activity is frequently observed in cancer and contributes to various aspects of cancer progression. This review focuses on TGFβ1’s contribution to tumor immune suppression and escape, with emphasis on the influence of this regulatory cytokine on the differentiation and function of dendritic cells and T cells. Clinical trials targeting TGFβ1 in cancer patients are also reviewed, and strategies for future therapeutic interventions that build on our current understanding of immune regulation by TGFβ1 are discussed. View Full-Text
Keywords: cancer; TGFβ1; dendritic cell; T cell; immune suppression; immunotherapy cancer; TGFβ1; dendritic cell; T cell; immune suppression; immunotherapy
Show Figures

Graphical abstract

MDPI and ACS Style

Hargadon, K.M. Dysregulation of TGFβ1 Activity in Cancer and Its Influence on the Quality of Anti-Tumor Immunity. J. Clin. Med. 2016, 5, 76. https://doi.org/10.3390/jcm5090076

AMA Style

Hargadon KM. Dysregulation of TGFβ1 Activity in Cancer and Its Influence on the Quality of Anti-Tumor Immunity. Journal of Clinical Medicine. 2016; 5(9):76. https://doi.org/10.3390/jcm5090076

Chicago/Turabian Style

Hargadon, Kristian M. 2016. "Dysregulation of TGFβ1 Activity in Cancer and Its Influence on the Quality of Anti-Tumor Immunity" J. Clin. Med. 5, no. 9: 76. https://doi.org/10.3390/jcm5090076

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop